VIROLOGICAL RESPONSE AND TOLERANCE TO BOCEPREVIR OR TELAPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN TRIPLE THERAPY IN HIV-HCV CO-INFECTED PATIENTS: REAL-LIFE FINDINGS FROM THE PAN STUDY

被引：0
|
作者：
Baumgarten, A. [1 ]
Holm, S. [2 ]
Lutz, T. [3 ]
Schranz, D. [4 ]
Mauss, S. [5 ]
Hillenbrand, H. [6 ]
Moll, A. [7 ]
Scholten, S. [8 ]
Schmidt, W. [9 ]
Goelz, J. [10 ]
Hintsche, B. [11 ]
Schleehauf, D. [10 ]
Fenske, S. [12 ]
Stephan, C. [13 ]
Prziwara, D. [14 ]
Koeppe, S.
Alshuth, U. [15 ]
Jaeger, H. [16 ]
机构：
[1] Mib Dienstleistung GmbH, Berlin, Germany
[2] Private Practice Dres Kuhlmann Holm Heiken, Hannover, Germany
[3] Infektiologikum, Frankfurt, Germany
[4] Private Practice Dres Schranz Fischer, Berlin, Germany
[5] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
[6] Ctr Med, City Ost, Germany
[7] Ctr HIV & Hepatol, Berlin, Germany
[8] Ctr Med Hohenstaufenring, Cologne, Germany
[9] Praxiszentrum Kaiserdamm, MVZ Aerzteforum Seestrasse, Berlin, Germany
[10] Praxiszentrum Kaiserdamm, Ctr Addict Med Hepatol & HIV, Berlin, Germany
[11] Ctr Infectiol & Hepatol, Berlin, Germany
[12] ICH Grindelpraxis, Infekt Epidemiol Ctr, Hamburg, Germany
[13] JW Goethe Univ Hosp, Dept Infect Dis, Frankfurt, Germany
[14] Praxisteam Mitte, Berlin, Germany
[15] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany
[16] MVZ Karlsplatz, HIV Res & Clin Care Ctr, Munich, Germany
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)61306-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1146
引用
收藏
页码：S464 / S464
页数：1
相关论文
共 50 条
  • [31] Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
    Minguez, Carlos
    Ortega, Enrique
    Flores, Juan
    Carmena, Jorge
    Masia, Mar
    Montero, Marta
    Reus, Sergio
    Tornero, Carlos
    Jose Galindo, Maria
    Garcia-Deltoro, Miguel
    Amador, Concepcion
    Maria Cuadrado, Jose
    Uso, Jorge
    Lopez-Aldeguer, Jose
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 95 - 96
  • [32] Insulin resistance in co-infected HCV/HIV patients: A negative factor influencing sustained response to peginterferon plus ribavirin
    Romero-Gomez, M.
    Tural, C.
    Sola, R.
    Martinez-Sierra, M. C.
    Viloria, M. M.
    Jimenez, M. D.
    Arizcorreta, A.
    Trabadela, C.
    Clotet, B.
    Planas, R.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S223 - S224
  • [33] VIROLOGICAL EFFICACY OF BOCEPREVIR (BOC) AND TELAPREVIR (TVR) PLUS PEGINTERFERON alfa-2a (P)/RIBAVIRIN (R) UNTIL WEEK 12 IN DRUG ADDICTED PATIENTS WITH GT-1 INFECTION: FIRST REAL LIFE REPORT
    Weber, B.
    Ablassmaier-Stuetzel, B.
    Naumann, U.
    Schleehauf, D.
    Bachner, C.
    Goelz, J.
    Bannout, F.
    Isernhagen, K.
    Gottberg, J.
    Forestier, N.
    Buescher, K. -G.
    Baumgarten, A.
    Backmund, M.
    Alshuth, U.
    Walcher, S.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S378 - S378
  • [34] SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN HIV-HCV G1 CO-INFECTED PATIENTS ACCORDING TO THE MAGNITUDE OF HCV RNA DECREASE AT WEEK 4 OF TREATMENT WITH PEGINTERFERON (PEGIFN) ALFA-2A (40KD) PLUS RIBAVIRIN (RBV) IN THE PARADIGM STUDY
    Sulkowski, Mark S.
    Slim, Jihad
    Sterling, Richard K.
    Hassanein, Tarek
    Sola, Ricard
    Serrao, Rosario
    Martorell, Claudia
    Bertasso, Anne
    Stancic, Saray
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2010, 52 (04) : 762A - 763A
  • [35] HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients
    Salmon, D.
    Bani-Sadr, F.
    Gilbert, C.
    Rosenthal, E.
    Valantin, M. A.
    Simon, A.
    Neau, D.
    Morlat, P.
    Loko, M. A.
    Wittkop, L.
    Dabis, F.
    JOURNAL OF CLINICAL VIROLOGY, 2015, 73 : 32 - 35
  • [36] Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy
    Morisco, Filomena
    Masarone, Mario
    Rosato, Valerio
    Camera, Silvia
    Granata, Rocco
    Tartaglione, Maria T.
    Coppola, Carmine
    Coppola, Nicola
    Salomone-Megna, Angelo
    Gentile, Ivan
    De Luna, Antonio
    Federico, Alessandro
    Precone, Davide
    Claar, Ernesto
    Abenavoli, Ludovico
    Persico, Marcello
    REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 306 - 316
  • [37] Triple Therapy Under Real Life Conditions: Telaprevir (TVR) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in NaiVE Patients Infected With Chronic Hepatitis C, Genotype 1. The PAN Study
    Moog, Gero
    Mauss, Stefan
    Hueppe, Dietrich
    Spengler, Ulrich
    Schott, Eckart
    Eisenbach, Christoph
    Schober, Andreas
    Heyne, Renate
    Jung, Maria-Christina
    Teuber, Gerlinde
    Doss, Margareta Frank
    Roessle, Martin
    Pape, Stefan
    Schuchmann, Marcus
    Alshuth, Ulrich
    Buggisch, Peter
    GASTROENTEROLOGY, 2013, 144 (05) : S983 - S983
  • [38] Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir
    Vo, Kevin P.
    Vutien, Philip
    Akiyama, Matthew J.
    Vu, Vinh D.
    Ha, Nghiem B.
    Piotrowski, Joy I.
    Wantuck, James
    Roytman, Marina M.
    Tsai, Naoky
    Cheung, Ramsey
    Li, Jiayi
    Nguyen, Mindie H.
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (04) : 1045 - 1051
  • [39] Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir
    Kevin P. Vo
    Philip Vutien
    Matthew J. Akiyama
    Vinh D. Vu
    Nghiem B. Ha
    Joy I. Piotrowski
    James Wantuck
    Marina M. Roytman
    Naoky Tsai
    Ramsey Cheung
    Jiayi Li
    Mindie H. Nguyen
    Digestive Diseases and Sciences, 2015, 60 : 1045 - 1051
  • [40] Histological response to peginterferon alfa-2A (40kd) (Pegasys®) plus ribavirin (Copegus®) in patients with HIV-HCV co-infection:: Results of the AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT).
    Lissen, E
    Clumeck, N
    Sola, R
    Correa, M
    Montaner, J
    Nelson, M
    Depamphilis, J
    Dieterich, DT
    HEPATOLOGY, 2004, 40 (04) : 241A - 241A
12345